Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment
Cell Proliferation · 2025
DOI: 10.1111/cpr.70125 ↗At a glance
Leserbrief in Cell Proliferation, 2025. Written by Yang Wu and 12 co-authors. Institution: Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Major MEDLINE topics: Deoxycytidine, Neoplastic Stem Cells, Pancreatic Neoplasms. Cited 5 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Jiangsu Province "Double-Creation Doctorate" Talent Program, Jiangsu Provincial Hospital of Traditional Chinese Medicine Excellent Doctoral Cultivation Program.
Abstract (original language)
ARPC1B+ cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy. Our study demonstrated that CK-636 can act as a rational adjuvant to overcome gemcitabine resistance in pancreatic cancer therapy.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
- Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
ORCID profiles: Yang Wu, Jianpeng Zhang, Weixiong Zhu, Wenjie Shi, Zhaokai Zhou
Funding
- National Natural Science Foundation of China
- Jiangsu Province "Double-Creation Doctorate" Talent Program
- Jiangsu Provincial Hospital of Traditional Chinese Medicine Excellent Doctoral Cultivation Program
- Jiangsu Provincial Health Commission Medical Research Project
- Science and Technology Innovation Project for Nanjing Overseas Chinese
- The Incubation Program of National Natural Science Foundation of Jiangsu Provincial People's Hospital
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- Postdoctoral Fellowship Program of CPSF
Cite
APA
Wu, Y., Zhang, J., Zhu, W., Zhu, X., Liu, Y., Wang, X., Zhao, T., Zhang, C., Zhang, Z., Shi, W., Shi, R., Zhou, Z., & Xu, S. (2025). Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Cell Proliferation. https://doi.org/10.1111/cpr.70125
Vancouver
Wu Y, Zhang J, Zhu W, Zhu X, Liu Y, Wang X, et al. Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Cell Proliferation. 2025. doi:10.1111/cpr.70125
BibTeX
@article{Wu2025,
author = {Wu, Yang and Zhang, Jianpeng and Zhu, Weixiong and Zhu, Xinrui and Liu, Yi and Wang, Xin and Zhao, Tianyu and Zhang, Chun and Zhang, Zili and Shi, Wenjie and Shi, Run and Zhou, Zhaokai and Xu, Shaohui},
title = {Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.70125}
}
EUVIMED